India’s Sun Pharma Estimates Taro Buyout At $21.3 Million
This article was originally published in PharmAsia News
Sun Pharmaceutical Industries of India now estimates its offer to buy all of Israel's Taro Pharmaceuticals will cost it about $21.3 million. The Indian drug maker has been trying to buy the Israeli firm ever since the companies had a falling out over a merger agreement just over two years ago. Each sued the other and Sun, which already owned 36 percent of Taro, has extended its open offer 10 times. Sun now is awaiting a decision by Israel's Supreme Court over the matter. Sun Chairman Dilip Shanghvi estimated the latest cost of the takeover. (Click here for more
You may also be interested in...
Bharat Biotech has joined hands with University of Wisconsin–Madison and US-based FluGen to develop a nasal vaccine against COVID-19, becoming one of only two entities taking the intranasal, more convenient route of administration. Separately, Bharat's chikungunya vaccine is expected to enter Phase III by December 2020.
Diagnostics company Bodysphere had to retract an announcement that it had received an emergency use authorization from the US FDA for a COVID-19 serologic test. See why Bethany Hills, an attorney with law firm Morrison & Foerster, says this may be a cautionary tale for other manufacturers.
Trademarks are registered and published for opposition with the US Patent and Trademark Office and are published weekly in the agency's Official Gazette.